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AMONG THE VARIOUS HORMONES pro-
duced by non-endocrine neoplasms,
placental hormones (viz. human placental
lactogen (hPL) and human chorionic
gonadotrophin (hCG)) are of particular
interest. Both hPL and hCG are produced
by syncytiotrophoblast of the normal
placenta, and are present in the circulation
in large quantities during pregnancy.
However, hCG has been detected in ex-
tracts ofnormal tissues, such as pituitary,
testes, colon, liver and gastric epithelium
(Braunstein et al., 1975; Vaitukaitis et al.,
1976; Yoshimoto et al., 1977). Similar re-
ports are not available with regard to
hPL, except for one study by Payne &
Ryan (1971), who showed the presence of
hPL in apparently normal testes of a
patient with carcinoma of the prostate.
hPL is not known to be elaborated in
various non-cancerous pathological con-
ditions even at the low level of 2 pg/ml of
serum (Weintraub & Rosen, 1971). Secre-
tions of hPL and hCG by carcinoma ofthe
breast have been observed in our earlier
studies (Sheth et al., 1974, 1977). The pre-
sent investigations deal with the ectopic
elaboration of hPL in the circulation of
patients with histologically diagnosed
tumours of the gastrointestinal (GI) tract.
In order to establish the secretion of hPL
as a truly ectopic product, hPL levels were
determined in extracts of tumour tissues
as well.
Blood samples were obtained from a
total of 60 patients presenting with
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tumours of the GI tract at the Tata
Memorial Hospital, Bombay. Histopatho-
logical confirmation was obtained. Tumour
tissues were collected from 13 of these
patients. Blood samples from 42 patients
with non-cancerous conditions of the GI
tract were also examined. In addition,
blood samples from 30 normal males and
30 normal non-pregnant females were
obtained as controls.
Sera and tumour tissues were stored at
- 20°C until assayed. Assays were carried
out within 30 days of collection of a
sample. Before use for radioimmunoassay
(RIA), each tissue was weighed, minced
under cold conditions and homogenized
in a Potter Elvehjem homogenizer in cold
phosphate-buffered saline (PBS) pH 7-0.
The homogenate was then centrifuged at
15,000 g for 30 min. RIA was carried out
by the double-antibody technique, accord-
ing to the method of Midgley (1966). All
samples were run in duplicate using 200
and 400 pl of serum or tumour extract.
The assay was repeated twice to confirm
the results. Samples were considered
positive only when total precipitable
counts were less than 80% of tubes with
no antigen.
Studies on a total of 42 patients not
harbouring any tumour but suffering from
other diseases of the GI tract showed that
serum hPL was undetectable in cases of
duodenal ulcer (18), ulcerative colitis (6),
gastritis (12), acute appendicitis (4), pan-
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TABLE. hPL in sera of patients with
neoplasms of the GI tract
Range
Neoplastic No. of No. (%) (ng/ml of
condition patients hiPL + serum)
Stomach 20 10 (50) 1 1-3-2
Rectum 20 7 (35) 1 0-2 6
Liver 9 5 (56) 1-6-2-2
Anal canal 6 2 (33) 1 0-2 5
Colon 2 0
Gall bladder 1 0
Pancreas 1 0
Bile duct 1 0
Total 60 24 (40) 1 0-3-2
the caecum (1). Serum hPL was also un-
detectable in 30 normal males and 30
normal non-pregnant women. As shown in
the Table, the overall retrospective inci-
dence of hPL+ sera was around 40%0 in
patients with tumours of the GI tract.
This incidence is considerably higher than
the 13% reported previously by other in-
vestigators (Weintraub & Rosen, 1971;
Rosen et al., 1975). The higher incidence
of hPL may be attributed to the highly
sensitive and specific antiserum used in
the present investigation. It may be noted
that this antiserum showed no cross-
reactivity with hGH and hPRL. Also,
false positive results were not observed
when the same antiserum was used to
examine sera from normal subjects or
from those with non-neoplastic diseases
of the GI tract. In addition, parallel
curves observed with standard hPL and
its ectopic counterpart indicated the
immunological homology between these
substances. In view of the high incidence
of serum hPL in patients with tumours of
the GI tract, and its undetectability in
normal subjects and in non-neoplastic
conditions, the possible use of hPL as a
marker in cancer seems to be worth con-
sidering.
The evidence that a hormone is a trulv
ectopic product entails its demonstration
in tumour tissue. The present study on 7
tumours shows that, whenever hPL was
detected in serum it was also present in
the tumour tissue, thus indicating that
the placental peptide is a tumour-asso-
ciated product. At the same time, the
possibility of ectopic hormone being pre-
sent in the tumour whilst it was un-
detectable in the circulation cannot be
ruled out. Hence the tumours from 6
patients whose sera were hPL- were also
examined. However, in the present study
no such instance was detected; tumours
were negative when sera were negative for
hPL.
Postoperative sera from onepatient with
carcinoma of the stomach remained posi-
tive for hPL after excision of the tumour.
It may be noted that this patient devel-
oped recurrence of the disease and died
subsequently. Another interesting case
was that of a patient with carcinoma of
the rectum, whose serum level of hPL
before radiotherapy was 2-5 ng/ml. How-
ever, after radiation therapy it was nega-
tive for hPL. It may be noted that this
patient had an 18-month complete re-
mission.
An interesting observation emerging
from the present studies is that the tumour
which did not show paraendocrine be-
haviour when checked earlier showed no
hormone during the follow-up. It is there-
fore suggested that if the tumour has no
ectopic secretion of hormone during its
earlier stage, it will probably not acquire
it during the later stages. This needs to be
checked in a large number of cases.
It appears that the secretion of hPL
may not be confined to advanced stages of
the disease, since the incidence of hPL
secretion in the earlier stage is similar to
that in the advanced stage. As tumours of
the GI tract pose a unique problem in
early detection owing to their anatomical
situation and delayed appearance of
symptoms, the evaluation of biochemical
markers in patients suspected of such
neoplasms is desirable.
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